Cardiovascular Health of Older Adults and Resveratrol (CORE) (CORE)

Inclusion Criteria:

All the criteria are the same as in the parent R01 (IRB201400439). Participants must meet all inclusion criteria listed below in order to participate in this study.

• Ability to understand study procedures and to comply with them for the entire length of the study;
• Age 65 years and older;
• Moderately functioning (i.e. a summary score of 4 - 12 on the Short Physical Performance Battery);
• Body Mass Index (BMI) range: 20-39.9 kg/m2;
• Willingness to undergo all testing procedures.

Exclusion Criteria:

All candidates meeting any of the exclusion criteria listed below at baseline will be disqualified from study participation.

• Non-English speaking individual.
• Failure to provide informed consent;
• Allergy/sensitivity to grapes or Japanese knotweed;
• Current dietary supplementation of grape seed extract or ginko biloba;
• Consumption of ≥ 8 oz. of red wine/dealcoholized red wine/red or purple grape juice more than once weekly;
• Consumption of any dietary supplements containing resveratrol, quercetin, or P. cuspidatum in the previous 90 days;
• Active treatment for cancer, stroke (< 6 months), peripheral vascular disease, coronary artery disease, myocardial infarction (< 6 months), congestive heart failure (stage III or IV), valvular heart disease, major psychiatric disease, severe anemia (blood levels of Hemoglobin < 8 g/dl), bleeding disorders or other blood disorders, liver or renal disease, diabetes, severe osteoarthritis, blindness or deafness, fracture in upper or lower extremity ( < 6 months), upper or lower extremity amputation, or Parkinson's disease;
• Cognitive impairment (i.e. Mini Mental Status Exam ≤ 23 & Clinical Dementia Rating ≥1);
• History of significant head injury;
• Physical activity (i.e. running, bicycling, etc.) ≥ 150 min/week;
• Excessive alcohol use (> 2 drinks/day) or alcohol abuse (> 5 drinks/day for males, or > 4 drinks/day for females);
• History of substance abuse within the past six months;
• Mood disorder (i.e. Center for Epidemiological Studies - Depression (CES-D) ≥ 16);
• History of tobacco use within the past three years;
• Resting heart rate > 120 bpm at screening visit;
• Systolic blood pressure > 160 mm Hg at screening visit;
• Diastolic blood pressure > 90 mm Hg at screening visit;
• Fasting glucose ≥ 126 mg/dL at screening visit;
• Abnormalities in blood chemistry parameters, defined by blood chemistry marker outside of healthy range) as determined by study physician

• Current use of

  • anabolic treatments (e.g. growth hormone or testosterone),
  • anticholinesterase inhibitor (e.g. Aricept),
  • hormone replacement (e.g. Estrogen),
  • anticoagulant therapies (note: aspirin -anti-platelet use (≤ 81mg/day) is permitted) or
  • use of anti-inflammatory medications more than 3 times per week.;
• Participation in another non-observational clinical trial, or has received an investigational product within 30 days prior to screening/enrollment;
• Refuse to refrain from CoQ10 or alpha-lipoic acid while enrolled in the study.

Temporary Exclusion Criteria

A person meeting any of the following temporary exclusion criteria at the time of screening would not be enrolled but may be re-screened at a later date. A period of 4 weeks is the minimum amount of time required before re-screening for the following conditions can be done.

• Recent bacterial/viral infection (< 2 weeks);
• Acute febrile illness in past 2 months;
• High blood pressure (i.e. ≥ 140/90 mm Hg but ≤ 160/90) at the screening visit; Major surgery or hip/knee replacement (< 6 months);